The sarcoma, alveolar soft part is a rare tumor. Its appearance on palpation most closely mimics that of a malignant fibrous tumor. These tumors have their origins in the mesothelium of the alveolar sacs, alveolar glands, or bone, and have a tendency towards local recurrence. The sarcoma, alveolar soft part is easily diagnosed on radiographs. The diagnosis of the sarcoma, alveolar soft part is based on the histological type, which in this case consists of the epithelial component. Treatment depends on the type of tumor.
The most common causes of sarcoma, alveolar soft part tumours involve radiation or an acute viral infection, both the main risk factors for cancers occurring of many tissues. The link between radiation and sarcoma is the first recognised example of a radiation-cancer relationship (except in breast cancer), despite the long history of ionising radiation use. Knowledge of the precise causal agents and ways of transmission that occur can help prevent further incidents of cancer.
Findings from a recent study show that it is possible to have a cure in this case. It depends on the stage of the tumor and on the type of treatment, but it is possible.
Each year, around 36,820 new cases of sarcoma, excluding leiomyosarcoma and soft tissue sarcoma, will be diagnosed in the US; excluding leiomyosarcoma and soft tissue sarcoma, this number is around 34,620. Sarcoma, excluding sarcomas of unknown origin, is thus the most common primary tumor of the soft tissue in US adults. However, this lesion is relatively rare when the whole cancer population is taken into account, comprising only 1.96% of all cancers in the USA in 2010. However, the incidence of sarcoma is markedly higher in men than in women, especially in the 30- to 49-year age group.
In this article, sarcoma, alveolar soft part, and soft part sarcoma are shown to have similar treatments that are mainly administered as palliative care options. Newer, more aggressive, or investigational treatments are the most likely to be found in the literature. More research on specific sarcoma and soft part sarcoma populations may be needed for more accurate treatment decisions.
There was no significant difference in the mean age at diagnosis between gender and race/ethnicity. There was no significant difference between sex and age groups or by race/ethnicity. There was no significant difference between sex and race/ethnicity. There was no significant difference between gender and age groups. Sex accounted for a significant amount of the variation in cancer severity and stage at diagnosis. The incidence and prevalence of sarcoma, alveolar soft part was significantly higher in Hispanics (P=0.003) and Latinos (P<0.00).
Sarcoma, alveolar soft part is an X-linked dominant disease. To confirm one diagnosis, it is best to have both parents tested and to have a panel of tests including multiplex PCR, fluorescent in situ hybridization, and direct sequencing.
There are two groups of patients with potential for developing sarcoma, alveolar soft part. The patients with a [prior history of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)] seem to develop sarcoma, alveolar soft part at a higher rate than non-lung cancer patients without a prior lung cancer. In a recent study, findings need to be verified with more patients but show a [possible correlation of prior lung cancer with sarcoma, alveolar soft part] to evaluate further and confirm possible risks and [correlations of prior non-cancer-related sarcoma with sarcomas other than lung carcinoma] to evaluate the true incidence of sarcomas in non-lung cancer patients.
Survival after definitive surgical treatment of sarcoma, alveolar soft part is excellent. Long-term survival is also possible with the new adjuvant treatment approaches. Survival depends on the specific tumor and can vary from months to more than 10 years.
The latest research into sarcoma, alveolar soft part showed promise that it can be treated with targeted therapy for metastatic disease in a nonirradiated setting. The data are consistent with reports of clinical activity with targeted therapy.